NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
Clinical Trials
110 trialsNCT03976323 2026-02-25
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03993353 2026-02-12
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
Phase 2 Completed
NCT03258554 2026-02-06
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
NCT00532155 2025-09-10
VITAL
Sanofi
Phase 3 Completed
NCT02185690 2025-08-21
MEK162
University Health Network, Toronto
Phase 1 Completed
NCT03795610 2025-07-25
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 2 Completed
NCT04939246 2025-07-17
SMART ONE
Baptist Health South Florida
Phase NA Completed
NCT05188729 2025-06-18
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT04362072 2025-06-11
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Pfizer
Phase 4 Completed
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT05233098 2025-03-06
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
Completed
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT05848947 2025-01-29
MAApping
Sirtex Medical
Phase 4 Completed
NCT01554397 2024-11-29
Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer
University of California, San Diego
Phase 2/3 Completed
NCT03941873 2024-10-26
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
BeiGene
Phase 1/2 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT03190265 2024-08-07
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01581840 2024-07-01
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT02164461 2024-05-20
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Advaxis, Inc.
Phase 1 Completed
NCT02705105 2024-04-25
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT00946881 2024-02-07
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 1/2 Completed
NCT03611556 2023-10-03
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
MedImmune LLC
Phase 1/2 Completed
NCT02412670 2023-07-10
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00176254 2023-05-16
Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
University of Kentucky
Phase 2 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT04033991 2023-04-06
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Pfizer
Completed
NCT01253161 2023-03-06
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01572493 2023-03-06
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03420742 2023-01-27
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
Phase 1 Completed
NCT02898116 2022-10-10
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02440425 2022-10-07
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00446446 2022-10-05
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Amgen
Phase 2 Completed
NCT01592721 2022-09-21
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT02920476 2022-06-23
UF-STO-LUNG-003
University of Florida
Phase 2 Completed
NCT00152477 2022-04-12
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
UCB Pharma
Phase 2 Completed
NCT02115542 2021-10-12
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed
NCT02367781 2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3 Completed
NCT03128008 2021-05-28
ADAPT
Duke University
Phase 2 Completed
NCT01755767 2021-04-06
METIV-HCC
Daiichi Sankyo
Phase 3 Completed
NCT01554371 2021-02-03
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
University of California, San Francisco
Phase 1/2 Completed
NCT02793128 2020-12-22
Olympus
UroGen Pharma Ltd.
Phase 3 Completed
NCT00420381 2020-12-19
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01519869 2020-12-14
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
University of Kentucky
Phase 2 Completed
NCT02392507 2020-11-19
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Eli Lilly and Company
Phase 2 Completed
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed